FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4311742334> ?p ?o ?g. }

• W4311742334 abstract "Abstract Introduction The mechanisms of cardiotoxicity during CAR-T cell therapy remain unclear to this day. We present the case of a 63-year-old woman with diffuse large B-cell lymphoma, who underwent CAR-T cell therapy. Five days after the infusion, she developed takotsubo cardiomyopathy. This is one of the rare cases of CAR-T cell-induced takotsubo cardiomyopathy. Case Description a 63-year-old woman with a diffuse large B-cell lymphoma and without significant cardiovascular history was treated with CAR-T cell therapy. The patient had arterial hypertension, dyslipidemia and history of CAD in the family. Prior to CAR-T cell therapy, she underwent baseline cardiac evaluation with an echocardiogram which showed a normal biventricular function. Within 24 hours of the infusion of CAR-T cells, she developed grade I cytokine release syndrome (CRS) with high-grade fever and sinus tachycardia. On day four, she developed grade three immune effector cell associated neurological syndrome which was treated with tocilizumab and dexamethasone. On day five laboratory testing showed a disproportionate elevation of BNP compared to hs-TnI. An ECG reported diffuse new-onset T wave inversion in all the precordial leads and a prolonged QT interval, and an echocardiogram showed severely reduced left ventricular ejection fraction (EF = 30%) with evidence of apical ballooning and right ventricular systolic dysfunction. Coronary angiography showed significant stenosis of the middle segment of the circumflex artery, which poorly could explain the clinical presentation of the patient. Ventriculography was also performed, which confirmed the ultrasound findings. During the next 48 hours, ECG and left ventricular function improved along with a gradual reduction of BNP and hs-TnI. We concluded that takotsubo syndrome was the most likely diagnosis. The InterTAK score was 89, which corresponded to a probability of takotsubo of 99.4%. The patient's therapy was then optimized with an increase in the dosage of angiotensin receptor antagonists and beta blockers. One month after CAR-T cell infusion, echocardiography showed complete recovery of biventricular function and ECG completely normalized, together with the values of BNP and TnI-hs. Medical treatment was left unmodified. Conclusions the pathophysiology of left ventricular systolic dysfunction during CAR-T cell therapy is unclear, but the main hypotheses are IL-6 mediated myocardial depression during CRS, stress-induced or takotsubo cardiomyopathy, and direct toxicity from CAR-T cells. From the currently available data from retrospective studies, cardiovascular events strongly overlap with CRS and, particularly, with high-grade CRS. Therefore, there is a strong rationale for early treatment with tocilizumab as it has been postulated from retrospective data a lower risk of cardiovascular events with earlier administration of tocilizumab during CRS. Surveillance for cardiotoxicity in patients receiving CAR-T cell therapy is mandatory for prompt recognition and treatment of cardiovascular complications. Our understanding of CAR-T cell-induced cardiomyopathy is still limited, and data regarding predictive factors for persistent cardiac dysfunction are lacking. It is important to differentiate cardiovascular events related to CAR-T cell therapy from epiphenomenon of CRS and capillary leak, to allow for a broader assessment of cardiac events among future CAR T-cell trials." @default.
• W4311742334 created "2022-12-28" @default.
• W4311742334 creator A5003623698 @default.
• W4311742334 creator A5003732920 @default.
• W4311742334 creator A5009229154 @default.
• W4311742334 creator A5015745084 @default.
• W4311742334 creator A5017866134 @default.
• W4311742334 creator A5022330993 @default.
• W4311742334 creator A5022525115 @default.
• W4311742334 creator A5023005663 @default.
• W4311742334 creator A5026872589 @default.
• W4311742334 creator A5034043080 @default.
• W4311742334 creator A5034405063 @default.
• W4311742334 creator A5037542950 @default.
• W4311742334 creator A5048942709 @default.
• W4311742334 creator A5049990932 @default.
• W4311742334 creator A5052858182 @default.
• W4311742334 creator A5059219223 @default.
• W4311742334 creator A5069997039 @default.
• W4311742334 creator A5074646524 @default.
• W4311742334 creator A5085979124 @default.
• W4311742334 date "2022-12-14" @default.
• W4311742334 modified "2023-10-15" @default.
• W4311742334 title "383 TAKOTSUBO SYNDROME AFTER CAR-T CELL INFUSION" @default.
• W4311742334 doi "https://doi.org/10.1093/eurheartjsupp/suac121.116" @default.
• W4311742334 hasPublicationYear "2022" @default.
• W4311742334 type Work @default.
• W4311742334 citedByCount "0" @default.
• W4311742334 crossrefType "journal-article" @default.
• W4311742334 hasAuthorship W4311742334A5003623698 @default.
• W4311742334 hasAuthorship W4311742334A5003732920 @default.
• W4311742334 hasAuthorship W4311742334A5009229154 @default.
• W4311742334 hasAuthorship W4311742334A5015745084 @default.
• W4311742334 hasAuthorship W4311742334A5017866134 @default.
• W4311742334 hasAuthorship W4311742334A5022330993 @default.
• W4311742334 hasAuthorship W4311742334A5022525115 @default.
• W4311742334 hasAuthorship W4311742334A5023005663 @default.
• W4311742334 hasAuthorship W4311742334A5026872589 @default.
• W4311742334 hasAuthorship W4311742334A5034043080 @default.
• W4311742334 hasAuthorship W4311742334A5034405063 @default.
• W4311742334 hasAuthorship W4311742334A5037542950 @default.
• W4311742334 hasAuthorship W4311742334A5048942709 @default.
• W4311742334 hasAuthorship W4311742334A5049990932 @default.
• W4311742334 hasAuthorship W4311742334A5052858182 @default.
• W4311742334 hasAuthorship W4311742334A5059219223 @default.
• W4311742334 hasAuthorship W4311742334A5069997039 @default.
• W4311742334 hasAuthorship W4311742334A5074646524 @default.
• W4311742334 hasAuthorship W4311742334A5085979124 @default.
• W4311742334 hasBestOaLocation W43117423341 @default.
• W4311742334 hasConcept C126322002 @default.
• W4311742334 hasConcept C164705383 @default.
• W4311742334 hasConcept C2778198053 @default.
• W4311742334 hasConcept C2778797674 @default.
• W4311742334 hasConcept C2780144208 @default.
• W4311742334 hasConcept C71924100 @default.
• W4311742334 hasConcept C78085059 @default.
• W4311742334 hasConceptScore W4311742334C126322002 @default.
• W4311742334 hasConceptScore W4311742334C164705383 @default.
• W4311742334 hasConceptScore W4311742334C2778198053 @default.
• W4311742334 hasConceptScore W4311742334C2778797674 @default.
• W4311742334 hasConceptScore W4311742334C2780144208 @default.
• W4311742334 hasConceptScore W4311742334C71924100 @default.
• W4311742334 hasConceptScore W4311742334C78085059 @default.
• W4311742334 hasIssue "Supplement_K" @default.
• W4311742334 hasLocation W43117423341 @default.
• W4311742334 hasOpenAccess W4311742334 @default.
• W4311742334 hasPrimaryLocation W43117423341 @default.
• W4311742334 hasRelatedWork W2051712573 @default.
• W4311742334 hasRelatedWork W2077083067 @default.
• W4311742334 hasRelatedWork W2091139515 @default.
• W4311742334 hasRelatedWork W2319805938 @default.
• W4311742334 hasRelatedWork W2355594703 @default.
• W4311742334 hasRelatedWork W3033076790 @default.
• W4311742334 hasRelatedWork W3035006171 @default.
• W4311742334 hasRelatedWork W3155674270 @default.
• W4311742334 hasRelatedWork W3187572025 @default.
• W4311742334 hasRelatedWork W4306255588 @default.
• W4311742334 hasVolume "24" @default.
• W4311742334 isParatext "false" @default.
• W4311742334 isRetracted "false" @default.
• W4311742334 workType "article" @default.